Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.
2025 · 1st Quarter (Jan 1 - Mar 31)
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
Filed by DLA PIPER LLP (US).
Open official filingSource-reported fields
Filing overview
- Type
- Registration
- Posted
- Mar 17, 2025
- Income
- Not reported
- Expenses
- Not reported
- Registrant
- DLA PIPER LLP (US)
- Filing UUID
- 98e18c66-7c50-42b9-9f40-c31fa71a57a8
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.
Policies and proposals impacting pharmaceutical development, approval, manufacturing, and reimbursement, including rebates and pricing. Medicare policies. Trade policies and agreements, including IP protections.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.